Physician profile
Vimalkumar Patel
NPI 1750776704
$5,428.09
in general payments reported to CMS, 2019-2025
21 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $2,357 · 2024: $805 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $2,356.53 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $729.60 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $301.49 | 2024-2025 | |
| Grifols USA, LLC | $263.39 | 2024-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $217.83 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $213.09 | 2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $194.61 | 2024-2025 | |
| Amgen INC. | $178.25 | 2024-2025 | Tavneos, Tezspire |
| Insmed, INC. | $141.00 | 2024-2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $140.22 | 2024-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.90 | 2025 | Ofev |
| Pharming Healthcare, INC. | $107.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $106.38 | 2025 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $84.69 | 2025 | |
| Abbvie INC. | $77.63 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $46.50 | 2025 | |
| Lilly USA, LLC | $41.88 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $33.25 | 2024 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $25.80 | 2025 | Lumryz |
| Philips North America LLC | $21.91 | 2024 | (Ak6) Vest Therapy |
| Gilead Sciences, INC. | $21.33 | 2024 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimalkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.